HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colgate

This article was originally published in The Rose Sheet

Executive Summary

"Quiet innovations," or product launches that are not highly publicized, are key to building Colgate's long-term business, CEO Reuben Mark says during recent presentation at the Morgan Stanley Global Consumer Conference in New York City. Exec cites Colgate launches such as Simply White and Max Fresh toothpastes, as well as the upcoming 360° toothbrush with tongue cleaner as examples of "quiet innovations" which will continue to generate sales. Mark also reassured analysts that Colgate's global business remains strong despite the firm's recent decision to lower its earnings targets for the third and fourth quarters (1"The Rose Sheet" Sept. 27, 2004, p. 8). Colgate will continue to focus on core categories and growing market share and expects earnings per share to be $.06-$.10 next year, he adds...

You may also be interested in...



Colgate Forecast Calls For Higher Volume, Lower Profit On Spending

Colgate's effort to boost marketing support to maintain leading share positions is fueling volume sales and market share growth, but also will result in lower than expected earnings in the second half of the year, Chairman and CEO Reuben Mark warned investors during a conference call Sept. 20

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

 

 

Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

UsernamePublicRestriction

Register

RS012604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel